Literature DB >> 7706304

Characterization of apolipoprotein J-Alzheimer's A beta interaction.

E Matsubara1, B Frangione, J Ghiso.   

Abstract

The main component of Alzheimer's amyloid deposits, A beta, has been found also as a soluble (sA beta) normal constituent of biological fluids and cell culture supernatants. Whether or not sA beta is the immediate precursor of A beta, it is clear that peptides with the same amino acid sequence can have both fibrillar and non-fibrillar conformations. The interconversion mechanism from one form to another is presently under intensive investigation. We have previously described that (i) a synthetic peptide A beta 1-40 immobilized on affinity matrices was able to retrieve apolipoprotein J (apoJ) from plasma and cerebrospinal fluid; and (ii) the interaction of sA beta with apoJ occurs in vivo, as demonstrated by the ability of anti-apoJ to co-precipitate sA beta from normal cerebrospinal fluid. We have characterized the binding between A beta 1-40 and apoJ and found that the interaction is saturable, specific, and reversible. The dissociation constant of 2 x 10(-9) M is indicative of high affinity binding. The stoichiometry of the reaction is 1:1; apoJ has five times more affinity for fresh A beta 1-40 than for the aggregated peptide. Competitive inhibition studies carried out with apolipoprotein E (isoforms E2, E3, and E4), transthyretin, vitronectin, and alpha 1-antichymotrypsin indicate that the complex apoJ.A beta 1-40 cannot be dissociated by any of these competitors at physiologic concentrations. The data strongly suggest that apoJ plays an important role as a carrier protein for sA beta.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706304     DOI: 10.1074/jbc.270.13.7563

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

Review 1.  Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations.

Authors:  Christiane Reitz
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice.

Authors:  M S Kindy; D J Rader
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

3.  Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers.

Authors:  B V Zlokovic; C L Martel; E Matsubara; J G McComb; G Zheng; R T McCluskey; B Frangione; J Ghiso
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

4.  Genetic ablation of apolipoprotein A-IV accelerates Alzheimer's disease pathogenesis in a mouse model.

Authors:  Yujie Cui; Mingwei Huang; Yingbo He; Shuyan Zhang; Yongzhang Luo
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

5.  Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation.

Authors:  S R Hughes; O Khorkova; S Goyal; J Knaeblein; J Heroux; N G Riedel; S Sahasrabudhe
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

6.  N-terminal region of myelin basic protein reduces fibrillar amyloid-β deposition in Tg-5xFAD mice.

Authors:  Ming-Hsuan Ou-Yang; Feng Xu; Mei-Chen Liao; Judianne Davis; John K Robinson; William E Van Nostrand
Journal:  Neurobiol Aging       Date:  2014-10-13       Impact factor: 4.673

Review 7.  Dyslipidemia and the risk of Alzheimer's disease.

Authors:  Christiane Reitz
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

8.  Mapping the interactions between the Alzheimer's Aβ-peptide and human serum albumin beyond domain resolution.

Authors:  Moustafa Algamal; Julijana Milojevic; Naeimeh Jafari; William Zhang; Giuseppe Melacini
Journal:  Biophys J       Date:  2013-10-01       Impact factor: 4.033

9.  A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; James A Ripellino; Yongsheng Li; Stephen D Schmidt; Paul M Mathews; John D Fryer; David M Holtzman; Einar M Sigurdsson; Thomas Wisniewski
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

10.  Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid.

Authors:  Maria Bjerke; Erik Portelius; Lennart Minthon; Anders Wallin; Henrik Anckarsäter; Rolf Anckarsäter; Niels Andreasen; Henrik Zetterberg; Ulf Andreasson; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.